Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom
作者: Cristina RebordosaJaume AguadoEstel PlanaSteven ThomasAna FrancesAlejhandra LeiEsther García-GilJavier NuevoSusana Perez-GutthannJordi Castellsague
作者单位: 1RTI Health Solutions, Av. Diagonal 605, 9-1, 08028, Barcelona, Spain
2RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC, 27709, United States
3AstraZeneca, Avda. Diagonal, 615 2nd floor, 08028, Barcelona, Spain
4AstraZeneca, Serrano Galvache 56, 28033, Madrid, Spain
刊名: Respiratory Medicine, 2019, Vol.152 , pp.37-43
来源数据库: Elsevier Journal
DOI: 10.1016/j.rmed.2019.04.018
关键词: AclidiniumLAMAMortalityUnited Kingdom
英文摘要: Abstract(#br)Background(#br)Aclidinium bromide is an inhaled long-acting muscarinic antagonist (LAMA). Although the initial potential increased cardiovascular and mortality risk among users of tiotropium has been ruled out by several observational studies, and clinical trials, there are still concerns related to the use of newer LAMA medications. The current study aimed to evaluate the risk of death among users of aclidinium and other LAMAs.(#br)Methods(#br)We conducted a cohort and nested case-control study among patients with COPD aged 40 years or older to compare the risk of all-cause mortality among users of aclidinium and other COPD medications with the risk among users of long-acting β2 agonists (LABA), in the Clinical Practice Research Datalink (CPRD) in the United Kingdom...
全文获取路径: Elsevier  (合作)
影响因子:2.585 (2012)

  • cohort 伙伴
  • United Kingdom UK联合王国
  • increase 增加
  • death 
  • study 学习